In this study we show that the CCR9 ligand CCL25 is expressed by normal colon epithelium; that levels of colonic CCL25 increase in both Crohn's disease and ulcerative colitis; and that pharmacological inhibitors of CCR9 prevent the development of disease in an experimental model of ulcerative colitis. Here, CCR9 is linked to ulcerative colitis.